
09 Jan 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/01/09/3216206/0/en/SEED-Therapeutics-Doses-First-Patient-in-Phase-1-Trial-of-ST-01156-a-Molecular-Glue-Degrader-Targeting-RBM39.html

11 Aug 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/08/11/3130780/0/en/FDA-Clears-IND-for-SEED-Therapeutics-RBM39-Degrader-ST-01156.html